Patient-Reported Outcomes Measures in Psoriasis
Psoriasis, a chronic systemic inflammatory disease, has a substantial impact on patients’ quality of life (QoL): physical limitations, psychologic impact, social embarrassment, and occupational burden, as well as treatment-related complications. This paper discusses some of the uses and limitations of commonly used patient-reported outcomes (PRO) in psoriasis. We reviewed 260 papers including original research and systemic review papers looking into the PRO used in psoriasis clinical trials. Although there is still no single best PRO measure in psoriasis nor in any other disease, it was interesting to examine the common instruments that are used in psoriasis clinical trials, especially those involving newly innovated biologics as Interleukin 17 inhibitors, and assessing the psychometric properties. The International Dermatology Outcome Measures works with patients, health care providers, payers, and regulators to develop validated patient-centered clinical outcome measures for clinical research as well as clinical practice.
Abdat, R., Lim, Y., Joshipura, D., Goldminz, A., & Gottlieb, A. B. (2017). Patient-Reported Outcomes Measures in Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2 (3), 41-46. https://doi.org/10.1177/247553031700200303
Originally published in Journal of Psoriasis and Psoriatic Arthritis, 2(3), 41-46. The original material can be found here.